1[1]Johnston EM,Crawford J. Hematopoietic growth factors in the reduction of chemotherapeutic toxicity[J]. Semin Oncol, 1998,25 :552-561
2[2]Calhoun DA,Christensen RD. Human developmental biology of granulocyte colony-stimulating factor[J]. Clin Perinatol, 2000,27: 559-576
3[3]Cairo MS. Neonatal neutrophil host defense. Prospects for immunologic enhancement during neonatal sepsis [J]. Am J Dis Child, 1989,143: 40-46
4[4]Dunn CJ, Goa KL. Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings[J]. Drugs, 2000,59 : 681-717
5[5]Martin-Christin F. Granulocyte colony stimulating factors: how different are they? how to make a decisin? [J] Anticancer Drugs,2001,12:185-191
6[6]van der Auwera P, Platzer E, Xu ZX, et al. Pharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (Ro 25-8315) in healthy volunteers :comparison with single and multiple daily doses of filgrastim [J]. Am J Hematol,2001,66:245-251
7[7]Ono M. Physicochemical and biochemical characteristics of glycosylated recombinant human granulocyte colony stimulating factor(lenograstim)[J]. Eur J Cancer,1994,30A(Suppl 3) :S7S11
8[8]Lowenberg B. Proliferative activity of rG-CSFs in cell line bioassays[J]. Int J Hematol,1996,64(Suppl 2) :S13-S14 z
9[9]Nissen C, Dalle Carbonare V, Moser Y. In vitro comparison of the biologic potency of glycosylated versus non-glycosylated rGCSF[J]. Drugs Invest, 1994,7:346-352
10[10]Smith MA, Smith JG. The use of granulocyte colony stimulating factor for treatment of autoimmune neutropenia[J]. Curr Opin Hematol , 2001,8 : 165-169
